Tagrisso access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Tagrisso

Tagrisso (osimertinib) is a third-generation EGFR tyrosine kinase inhibitor (T790M-active) approved by the US Food and Drug Administration for EGFR-mutated non-small cell lung cancer in adjuvant and metastatic settings. The current FDA label is available at accessdata.fda.gov. Tagrisso is marketed by AstraZeneca. Reserve Meds coordinates US-sourced cross-border access to Tagrisso under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Tagrisso in each jurisdiction Reserve Meds has authored.

Tagrisso country-specific access guides

Reserve Meds has published 12 country-specific access guides for Tagrisso. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Arabic-language guides are available for: Abu Dhabi, Bahrain, Dubai, India, Kuwait, Qatar, Saudi Arabia, UAE. Switch languages via the page footer or the URL prefix /ar/.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Tagrisso in the 12 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Tagrisso. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Tagrisso access scope for your country

Related Reserve Meds resources

• Access pathways index (named-patient, personal-import, hospital-exemption, and equivalent frameworks by country)
• Conditions index (the indication families Reserve Meds coordinates around)
• Drug catalog (all FDA-labeled medicines in the Reserve Meds coordination scope)
• All country-specific access guides
• How Reserve Meds coordinates a cross-border case
• Trust, compliance, and editorial review

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.